标准和超免疫静脉注射免疫球蛋白对近期流行的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和活性
Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating SARS-CoV-2 Variants.
作者信息
Liu Dongxiao, Bellusci Lorenza, Golding Hana, Khurana Surender
机构信息
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.
出版信息
Vaccines (Basel). 2025 Jul 17;13(7):760. doi: 10.3390/vaccines13070760.
Our study demonstrates that IVIG lots manufactured in 2023-2024 contain neutralizing antibodies against circulating Omicron variants, including KP.3 and XEC. These variants are resistant to all convalescent plasma and IVIG preparations produced prior to 2023. Therefore, recent IVIG lots may provide some protection against COVID-19 caused by circulating SARS-CoV-2 variants.
我们的研究表明，2023 - 2024年生产的静脉注射免疫球蛋白（IVIG）批次含有针对循环中的奥密克戎变体（包括KP.3和XEC）的中和抗体。这些变体对2023年之前生产的所有康复期血浆和IVIG制剂均具有抗性。因此，近期的IVIG批次可能为预防由循环中的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体引起的新冠肺炎提供一定保护。
Zotero 插件